« Back
Home /
Rimonabant

Rimonabant

Manufacturer	TargetMol
Category	Reagents & Chemicals Biochemicals
Type	Chemicals
Specific against	other
Amount	1ml
Item no.	TMO-T1519L-1ml
CASRN	168273-06-1
eClass 6.1	32160000
eClass 9.0	32160000
Available
Alias	Antibacterial,Acyltransferase,Acyltransferase,Cannabinoid Receptor, SR141716
Short Description	Rimonabant is an inverse agonist for the cannabinoid receptor CB1. It is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. Its main avenue of effect is a reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States.
Shipping	cool pack
Storage	-20°
Target names or alias	SR141716
Molecular Weight	463, 79
Pathway	Metabolism\|\|\|GPCR/G Protein\|\|\|Microbiology/Virology
Target	Antibacterial\|\|\|Cannabinoid Receptor\|\|\|Acyltransferase

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 1ml

available

Delivery expected until 7/26/2024

Express Delivery: Save 4 days

Compare

Add to wishlist

Recommend by mail